SCHEMBL18072358

SCHEMBL18072358

CC(C)(C)OC(=O)NCc1cc(CCl)nc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1H O95180 1/20 0.43
▸ CACNA1B Q00975 1/20 0.43
▸ CACNA1C Q13936 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAP3K5 Q99683 1/20 0.41
▸ KDM4A O75164 1/20 0.39
▸ STK17B O94768 1/20 0.39
▸ STK17A Q9UEE5 1/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ TRPV1 Q8NER1 2/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ NAMPT P43490 1/20 0.37
▸ NSD2 O96028 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ CYP3A4 P08684 1/20 0.36
▸ ACACB O00763 1/20 0.36
▸ ACACA Q13085 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18072436 0.89 CACNA1H (0.44) CACNA1HCACNA1BCACNA1CL3MBTL1MAP3K5
SCHEMBL18072351 0.89 CACNA1H (0.46) CACNA1HCACNA1BCACNA1CL3MBTL1MAP3K5
SCHEMBL19755699 0.84 L3MBTL1 (0.44) CACNA1HCACNA1BCACNA1CL3MBTL1KDM4A
SCHEMBL18072434 0.82 CACNA1H (0.45) CACNA1HCACNA1BCACNA1CL3MBTL1MAP3K5
SCHEMBL18049996 0.82 TACR1 (0.38) CYP3A4
SCHEMBL18072457 0.81 CACNA1H (0.43) CACNA1HCACNA1BCACNA1CL3MBTL1MAP3K5
SCHEMBL16532758 0.79 GAA (0.48) CACNA1HCACNA1BCACNA1CL3MBTL1KDM4A
SCHEMBL8247006 0.79 LOXL2 (0.47) CACNA1HCACNA1BCACNA1CL3MBTL1MAP3K5
SCHEMBL18072471 0.78 CACNA1H (0.41) CACNA1HCACNA1BCACNA1CL3MBTL1MAP3K5
SCHEMBL20399840 0.78 CACNA1H (0.45) CACNA1HCACNA1BCACNA1CL3MBTL1KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2021-07-27 — — US disclosed
CN-107592861-B Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof 法玛克亚公司 2021-06-08 — — CN disclosed
EP-3795568-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF Pharmakea, Inc. (US) 2021-03-24 — — EP disclosed
EP-3265456-B1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2020-11-18 — — EP disclosed
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2020-04-16 — — US disclosed
US-10570094-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2020-02-25 — — US disclosed
US-20190119211-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2019-04-25 — — US disclosed
WO-2016144703-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2016-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119211-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX CACNA1H 4259/4885CACNA1B 3589/4885CACNA1C 3337/4885
US-10570094-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX CACNA1H 4259/4885CACNA1B 3589/4885CACNA1C 3337/4885
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX CACNA1H 4259/4885CACNA1B 3589/4885CACNA1C 3337/4885
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX CACNA1H 4259/4885CACNA1B 3589/4885CACNA1C 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback